Meeting
2020 Genitourinary Cancers Symposium
Randomized phase II study of docetaxel (D) + abiraterone acetate (AA) versus D after disease progression to first-line AA in metastatic castration-resistant prostate cancer (mCRPC): ABIDO-SOGUG Trial.
Authors
Miguel Angel Climent Duran
Instituto Valenciano de Oncología, Valencia, Spain
Miguel Angel Climent Duran , Albert Font , Ignacio Duran , Javier Puente , Daniel Castellano , M Isabel Sáez , Maria Jose José Mendez Vidal , Carmen Santander , Jose Angel Arranz Arija , Aranzazu Gonzalez del Alba , Alfredo Sanchez-Hernandez , Emilio Esteban , Teresa Alonso Gordoa , Pablo Maroto , Martín Emilio Lázaro Quintela , Javier Cassinello , Begona Perez Valderrama , María José Juan Fita , Begona Mellado
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02036060
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 95)
Abstract #
95
Poster Bd #
D19
Abstract Disclosures
Similar Posters
Poster
2015 Genitourinary Cancers Symposium
Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Alice Clement-Zhao
Poster
2013 Genitourinary Cancers Symposium
A phase I/II study of safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): Updated phase II results.
First Author: Daniel Petrylak
Poster
2024 ASCO Genitourinary Cancers Symposium
LORIKEET: A phase 2, randomized, open-label study of lorigerlimab plus docetaxel versus docetaxel alone in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Sumit Kumar Subudhi
Poster
2023 ASCO Genitourinary Cancers Symposium
Effect of neuroendocrine differentiation on therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancer.
First Author: Nanwei Xu